Clinical Trial Diversity

Clinical trial diversity helps build healthier communities.

A lack of diversity among principal investigators and within patient populations participating in clinical trials is often one of the most significant contributors to lower efficacy rates when new therapies hit the market.

Diverse clinical trials drive progress and provide patients with early access to new treatments.

Underrepresentation of patient populations in clinical trials undermines health equity for patients around the world; introduces unacceptable risk that new therapies entering the market may cause adverse reactions in different patient cohorts; and can leave billions of dollars of investment hanging in the balance. It is paramount that the patient segments and investigators represented in the clinical trials be as diverse and inclusive as possible.

Diversity in clinical trials is a universal imperative.

Inclusion is the precursor to building trust between patients and doctors and the bridge to a more equitable healthcare system for all. Both the public and private sectors have initiated efforts to address clinical trial diversity. The Food and Drug Administration (FDA) has issued guidance to encourage diversity from the design to execution of clinical product development. Meanwhile, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced the release of industry-wide principles on clinical trial diversity.

Continuously updated. Ever expanding. Always intelligent.

H1 embeds diversity and inclusion data within its solutions to provide clinical operations and feasibility teams granular insights into HCPs, patients, and trial sites that can help build equitable clinical trials. We aggregate and maintain a vast repository of diversity and social determinants of health data, performance data, and medical claims data sources covering more than 420,000 clinical trials globally. Our AI-powered analytics engine can identify diverse principal investigators, diverse patient populations, and the best trial sites to improve clinical trial diversity and health equity.

With H1 you can:

Understand patient population distribution by age and gender at the state, city, or zip code levels.

Test and verify hypotheses on patient populations and get baseline measurement.

Increase trust among underrepresented patients with diverse principal investigators.

Target diverse populations who might be eligible to participate in current and upcoming clinical studies.

Ways Life Sciences Benefit from H1 for Equitable Clinical Trials

Diverse circle of people

 Holistic View of Diversity

Holistic View of Diversity

We provide a holistic view both in terms of statistical facets (age, gender, ethnicity) and diversity of thought (advocacy, influence, and outreach) in one intuitive platform.

Data bank

Comprehensive Data

Comprehensive Data

We aggregate information on 420k+ clinical trials, 10M+ HCPs, and diversity data for more than 2M+ HCPs.


Performance Benchmarking

Performance Benchmarking

H1 ingests client-provided data like output from Clinical Trial Management Systems and augments it to provide internal performance benchmarks vs. industry benchmarks to enable smarter engagement and selection strategies.